Laboratorios Farmaceuticos Rovi, S.A. (VIE:ROVI)

Austria flag Austria · Delayed Price · Currency is EUR
81.05
-0.75 (-0.92%)
At close: Mar 4, 2026
49.82%
Market Cap 4.16B
Revenue (ttm) 743.48M
Net Income (ttm) 140.44M
Shares Out n/a
EPS (ttm) 2.75
PE Ratio 29.59
Forward PE 26.73
Dividend 0.76 (0.93%)
Ex-Dividend Date Jul 14, 2025
Volume n/a
Average Volume 3
Open 81.20
Previous Close 81.80
Day's Range 80.40 - 81.70
52-Week Range 45.82 - 84.80
Beta n/a
RSI 64.14
Earnings Date Feb 25, 2026

About VIE:ROVI

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+,... [Read more]

Industry Pharmaceutical Preparations
Founded 1946
Employees 2,188
Stock Exchange Vienna Stock Exchange
Ticker Symbol ROVI
Full Company Profile

Financial Performance

In 2025, VIE:ROVI's revenue was 743.48 million, a decrease of -2.65% compared to the previous year's 763.75 million. Earnings were 140.44 million, an increase of 2.60%.

Financial Statements

News

Laboratorios Farmaceuticos Rovi SA (STU:41L) Q4 2025 Earnings Call Highlights: Strategic Growth ...

Laboratorios Farmaceuticos Rovi SA (STU:41L) Q4 2025 Earnings Call Highlights: Strategic Growth Amid Revenue Challenges

5 days ago - GuruFocus

Q4 2025 Laboratorios Farmaceuticos ROVI SA Earnings Call Transcript

Q4 2025 Laboratorios Farmaceuticos ROVI SA Earnings Call Transcript

5 days ago - GuruFocus

Laboratorios Farmaceuticos Rovi SA (WBO:ROVI) Q4 2024 Earnings Call Highlights: Navigating ...

Laboratorios Farmaceuticos Rovi SA (WBO:ROVI) Q4 2024 Earnings Call Highlights: Navigating Challenges and Seizing Growth Opportunities

1 year ago - GuruFocus